Patients were followed from 1 year after cohort entry until a diagnosis of incident adverse CVEs, switch to a comparator drug, any cause of death or the end of the study (30 September 2022), whichever occurred first
GLP-1RA-induced reductions in protein intake, lower insulin/IGF-1 and negative energy balance converge to suppress mTOR signaling, reducing muscle protein synthesis [31]
They share common GI side effects, such as nausea, diarrhea, and vomiting
Retatrutide (LY-3437943) is an investigational drug developed by Eli Lilly that acts as a triple hormone receptor agonist : GLP-1 (glucagon-like peptide-1) receptor agonist GIP (glucose-dependent insulinotropic polypeptide) receptor agonist Glucagon receptor agonist - read about why this is so important here This triagonist approach amplifies the metabolic impact seen with GLP-1 and GIP combinations like tirzepatide, while also leveraging glucagons thermogenic and energy-expending properties
The goal is to improve how the body functions, reduce long-term health risks, and help patients feel better with a plan that fits their needs
Candidates for Tirzepatide weight loss injections typically include adults with a Body Mass Index (BMI) of 30 or greater